EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Rhea-AI Summary

EyePoint (Nasdaq: EYPT) granted non-statutory inducement stock options to three new employees to purchase an aggregate of 13,900 shares of common stock. The options were granted on January 15, 2026 with an exercise price of $15.84 per share (the January 15 closing price), a 10-year term, and vesting over 4 years (25% after one year, then monthly over three years). Grants were approved by the Compensation Committee and made under NASDAQ Listing Rule 5635(c)(4) as inducement awards, with vesting conditioned on continued service.

News Market Reaction – EYPT

-4.80%

1 alert

-4.80% News Effect

-$66M Valuation Impact

$1.31B Market Cap

1K Volume

On the day this news was published, EYPT declined 4.80%, reflecting a moderate negative market reaction. This price movement removed approximately $66M from the company's valuation, bringing the market cap to $1.31B at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Inducement option shares: 13,900 shares New employees: 3 employees Exercise price: $15.84 per share +3 more

6 metrics

Inducement option shares 13,900 shares Options to new employees under NASDAQ Listing Rule 5635(c)(4)

New employees 3 employees Recipients of inducement stock option grants

Exercise price $15.84 per share Closing price on January 15, 2026; option strike price

Option term 10 years Contract life of inducement stock options

Vesting period 4 years Standard vesting schedule for granted options

Initial vesting 25% at 1 year Portion vesting on first anniversary of grant date

Market Reality Check

Price: $13.64 Vol: Volume 1,579,009 vs 20-da...

normal vol

$13.64 Last Close

Volume Volume 1,579,009 vs 20-day average 1,153,057 (relative volume 1.37x). normal

Technical Price $15.84 is trading above the 200-day MA of $11.19 and 17.11% below the 52-week high.

Peers on Argus

EYPT was at $15.84, down 0.5% over 24h. Peers were mixed: QURE (-0.25%), OCS (-0...

EYPT was at $15.84, down 0.5% over 24h. Peers were mixed: QURE (-0.25%), OCS (-0.04%), PRAX (-0.86%), URGN (+4.32%), UPB (-4.69%), indicating stock-specific dynamics rather than a coordinated sector move.

Historical Context

5 past events · Latest: Jan 07 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 07	Corporate update	Positive	+3.0%	Outlined DURAVYU milestones, completed Phase 3 enrollment, and cash runway into Q4 2027.
Dec 17	Conference appearance	Neutral	-1.6%	Announced CEO presentation and webcast at J.P. Morgan Healthcare Conference.
Dec 16	Inducement grants	Neutral	+3.2%	Granted options for 137,000 shares to new employees under NASDAQ Rule 5635(c)(4).
Nov 19	Clinical safety update	Positive	+2.3%	DSMC recommended Phase 3 DURAVYU wet AMD trials continue with no protocol changes.
Nov 17	Inducement grants	Neutral	+13.4%	Issued non-statutory stock options totaling 31,000 shares as inducement awards.

Pattern Detected

Recent value-driving moves have come from clinical and corporate milestones, while routine items like inducement grants and conference notices have shown mixed, generally smaller reactions.

Recent Company History

Over the last few months, EYPT has highlighted progress on DURAVYU, including a positive DSMC recommendation for its pivotal Phase 3 LUGANO and LUCIA wet AMD trials and a corporate update detailing >900 patients enrolled and key 2026 milestones. Capital-raising via offerings and ATM capacity extended cash runway into Q4 2027. Alongside these, EYPT has periodically reported NASDAQ Rule 5635(c)(4) inducement option grants. Today’s new-hire option awards fit this pattern of routine compensation-related disclosures rather than a fundamental business update.

Market Pulse Summary

This announcement details routine inducement stock option grants totaling 13,900 shares to three new...

Analysis

This announcement details routine inducement stock option grants totaling 13,900 shares to three new employees under NASDAQ Listing Rule 5635(c)(4), with a $15.84 exercise price, 10-year term, and four-year vesting. It adds incremental equity-based compensation but no new information on DURAVYU or financial guidance. In context of recent clinical and financing milestones, this is a standard HR-related disclosure; investors may focus more on upcoming Phase 3 data and cash runway metrics.

Key Terms

nasdaq listing rule 5635(c)(4), non-statutory stock options, exercise price

3 terms

nasdaq listing rule 5635(c)(4) regulatory

"as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

non-statutory stock options financial

"announced that the Company granted non-statutory stock options to new employees as inducement awards"

Non-statutory stock options are a type of reward that companies give to employees, allowing them to buy company shares at a set price within a certain period. Unlike formal or government-approved plans, these options are more flexible but may have different tax implications. For investors, they can influence a company's stock price and financial health, making them an important factor to consider.

exercise price financial

"The option awards have an exercise price of $15.84 per share, the closing price"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

AI-generated analysis. Not financial advice.

WATERTOWN, Mass., Jan. 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).

The Company granted stock options to purchase up to an aggregate of 13,900 shares of EyePoint common stock to three new employees. The stock options were granted on January 15, 2026. The grants were approved by the Compensation Committee and made as an inducement material to each employee entering into employment with EyePoint in accordance with NASDAQ Listing Rule 5635(c)(4). The option awards have an exercise price of $15.84 per share, the closing price of EyePoint’s common stock on January 15, 2026. The options have a ten-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee’s date of grant and the remainder vesting in equal monthly installments over the following three years. Vesting of the options is subject to the employee’s continued service with EyePoint through the applicable vesting dates.

About EyePoint

EyePoint, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU^™, is an innovative investigational sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, in next-generation bioerodible Durasert E^™ technology. Supported by robust safety and efficacy data across multiple clinical trials and indications, DURAVYU is currently being evaluated in Phase 3 pivotal trials for wet age-related macular degeneration with expected topline data beginning in mid-2026. First patient dosing in the pivotal Phase 3 clinical trials in diabetic macular edema is expected in the first quarter of 2026.

The Company is committed to partnering with the retina community to improve patient lives while creating long-term value, with four approved drugs over three decades and tens of thousands of eyes treated with EyePoint innovation.

EyePoint is headquartered in Watertown, Massachusetts, with a commercial manufacturing facility in Northbridge, Massachusetts.

Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.

DURAVYU^™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.

Investors:
Tanner Kaufman / Jenni Lu
FTI Consulting
Direct: 203-722-8743 / 667-321-6018
Tanner.Kaufman@fticonsulting.com / jenni.lu@fticonsulting.com

Media Contact:
Amy Phillips
Green Room Communications
Direct: 412-327-9499
aphillips@greenroompr.com

FAQ

What did EyePoint (EYPT) announce on January 16, 2026 about employee stock options?

EyePoint announced inducement grants of non-statutory options for three new employees to buy a total of 13,900 shares, granted on January 15, 2026.

What is the exercise price and term of the EyePoint (EYPT) inducement options?

The options have an exercise price of $15.84 per share and a 10-year term.

How do the EyePoint (EYPT) inducement options vest?

Options vest over 4 years: 25% on the first anniversary of the grant and the remainder in equal monthly installments over the following three years, subject to continued service.

Under what rule were the EyePoint (EYPT) inducement awards granted?

The grants were made as inducement awards in accordance with NASDAQ Listing Rule 5635(c)(4) and were approved by the Compensation Committee.

How many employees received EyePoint (EYPT) inducement option grants and what is the aggregate share amount?

Three new employees received option grants to purchase an aggregate of 13,900 shares of EyePoint common stock.